A new oral drug designed to improve efficacy of radiotherapy has been shown to be effective and safe as an adjunctive treatment for hard-to-treat cancers.
In a recent Phase II trial involving 35 patients with tumors with AKT mutations capivasertib, an AKT inhibitor, has demonstrated signs of effectiveness.
Authors discuss the results of this observational real-world study and how sequencing tyrosine kinase inhibitors can extend chemotherapy-free treatment time.
In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
A new study, published in CNS Oncology estimates the survival benefit of adding tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.